Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Y Ku

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
The Lancet. Oncology|September 4, 2023
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trialSamuel L Cytryn, Ryan H Moy, Darren Cowzer, et al.
Cancer Discovery|November 23, 2018
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric CancerFrancisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.
Cancer Discovery|November 11, 2017
Genetic Predictors of Response to Systemic Therapy in Esophagogastric CancerYelena Y Janjigian, Francisco Sanchez-Vega, Philip Jonsson, et al.
Nature Genetics|January 16, 2019
Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert M Samstein, Chung-Han Lee, Alexander N Shoushtari, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
The Lancet. Oncology|September 4, 2023
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trialSamuel L Cytryn, Ryan H Moy, Darren Cowzer, et al.
Cancer Discovery|November 23, 2018
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric CancerFrancisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.
Cancer Discovery|November 11, 2017
Genetic Predictors of Response to Systemic Therapy in Esophagogastric CancerYelena Y Janjigian, Francisco Sanchez-Vega, Philip Jonsson, et al.
Nature Genetics|January 16, 2019
Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert M Samstein, Chung-Han Lee, Alexander N Shoushtari, et al.
Pageof 11